Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) Short Interest Update

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) was the recipient of a significant decline in short interest in the month of September. As of September 15th, there was short interest totaling 331,600 shares, a decline of 33.4% from the August 31st total of 498,200 shares. Currently, 3.5% of the shares of the stock are sold short. Based on an average trading volume of 523,000 shares, the short-interest ratio is presently 0.6 days. Based on an average trading volume of 523,000 shares, the short-interest ratio is presently 0.6 days. Currently, 3.5% of the shares of the stock are sold short.

Theriva Biologics Price Performance

NYSEAMERICAN:TOVX opened at $0.52 on Wednesday. The business’s 50-day moving average price is $0.42 and its 200 day moving average price is $0.64. The firm has a market cap of $5.03 million, a P/E ratio of -0.02 and a beta of 0.65. Theriva Biologics has a 52-week low of $0.37 and a 52-week high of $2.64. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.15.

Theriva Biologics Company Profile

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.